Download alert-06-ontarget-nejm_2008_358_online

Baseline Characteristics of the Patients* - Part I
The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Baseline Characteristics of the Patients* - Part II
The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Discontinuation of Study Medications and Selected
Reasons for Permanent Discontinuation*
The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Kaplan-Meier Curves for the Primary Outcome
in the Three Study Groups
The composite primary outcome was death from cardiovascular causes,
myocardial infarction, stroke, or hospitalization for heart failure
The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Relative Risk of the Primary Outcome
and of the Main Secondary Outcome
The primary composite outcome was death from cardiovascular causes,
myocardial infarction, stroke, or hospitalization for heart failure.
The main secondary outcome was death from cardiovascular causes,
myocardial infarction, or stroke, which was used as the primary outcome in
the Heart Outcomes Prevention Evaluation (HOPE) trial.
The P value is for the comparison with the noninferiority margins
The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Incidence of the Primary Outcome,
Its Components, and Death from Any Cause
The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Secondary and Other Outcomes
The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Relative Risks in Prespecified Subgroups
Comparisons between the telmisartan and the ramipril group
(The risk score from the Heart Outcomes Prevention Evaluation (HOPE) trial ranges from 2.350 to 5.928, with
higher scores indicating higher risk. The sizes of the squares are proportioned to the numbers of events
The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Relative Risks in Prespecified Subgroups
Comparisons between the combination-therapy
(telmisartan plus ramipril) group and the ramipril group
(The risk score from the Heart Outcomes Prevention Evaluation (HOPE) trial ranges from 2.350 to 5.928, with
higher scores indicating higher risk. The sizes of the squares are proportioned to the numbers of events
The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Patient Eligibility Criteria - Inclusion criteria
The ONTARGET Investigators. NEJM 2008 Supplementary Appendix
Patient Eligibility Criteria – Exclusion criteria
The ONTARGET Investigators. NEJM 2008 Supplementary Appendix